MDGL

MKT CAP:$12B

Madrigal Pharmaceuticals Inc

Market Cap

$12B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$550.25-$43.62 (-7.35%)

Jul 15, 2026

52W High $602.8352W Low $289.88

Company Details

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone re...

Leadership

William J. Sibold

CEO, President & Director

Rebecca A. Taub M.D.Founder

Founder, Senior Scientific & Medical Advisor and Director

Mardi C. Dier

Executive VP & CFO

Shannon Kelley

Executive VP, Chief Legal Officer & Corporate Secretary

Carole Huntsman

Executive VP & Chief Commercial Officer

David Soergel M.D.

Executive VP & Chief Medical Officer

Mark Underwood

Executive Vice President of Business Planning & Operations

Rita Thakkar

Senior VP & Chief Accounting Officer

Ronald Filippo

Executive VP & Chief Information Officer

Tina E. Ventura

Chief Investor Relations Officer

IPO Date

Feb 6, 2007

Website

www.madrigalpharma.com

Key Metrics TTM

Revenue

$15M

- YoY

Net Income

-$510M

EPS (Diluted)

Free Cash Flow

-$272M

Revenue / Share

$0.68

Gross Margin

92.6%

Operating Margin

-3622.7%

Net Margin

-3487.1%

FCF Margin

-1861.0%

P/S

847.9x

P/E

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee